Adjuvant nivolumab plus ipilimumab for kidney cancer
Adjuvant therapy is medication that is given after surgery to [...]
Nivolumab compared to cabozantinib as a second- or third-line treatment
This study looked at real world data from people with [...]
Cabozantinib plus nivolumab and ipilimumab delays progression in kidney cancer
Preliminary results from the COSMIC-313 clinical trial have ben released. [...]
Statins improve the effectiveness of nivolumab for advanced kidney cancer
Statins are a group of medicines that can help lower [...]
Does the size of response to cabozantinib plus nivolumab affect clinical outcomes?
Ongoing results from the phase 3 CheckMate-9ER clinical trial with [...]
MEDI0680 plus durvalumab compared to nivolumab in patients with advanced kidney cancer
MEDI0680 and durvalumab are both immunotherapies called checkpoint inhibitors. They [...]
EIKCS 2022: Novel combination therapy shows promise in advanced kidney cancer
A combination therapy with a new targeted therapy (tyrosine kinase [...]
Genetic biomarkers for the survival of kidney cancer patients
Previously, researchers found some genes that helped identify which patients [...]
Nivolumab plus ipilimumab and live bacteria supplements in advanced kidney cancer
Researchers are interested in the bacteria in our gut (the [...]
Ipilimumab plus nivolumab combination approved for use on the NHS
The National Institute for Health and Care Excellence (NICE) has [...]
